Bakteryel ve Fungal Keratit Tedavisinde Yenilikler

yildirim, nilgün; Atalay, Eray

Bakteryel ve Fungal Keratit Tedavisinde Yenilikler

Nilgün YILDIRIM, (*Osmangazi Üniversitesi Tıp Fakültesi Göz Hastalıkları Ana Bilim Dalı, Eskişehir)

Eray ATALAY (Özel Derindere Hastanesi, İstanbul)

MN Oftalmoloji

22 0

Yıl: 2017 Cilt: 24 Sayı: 1 Korneada Yenilikl Sayfa Aralığı: 29 - 40 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Bakteryel ve Fungal Keratit Tedavisinde Yenilikler

Öz:

Enfeksiyöz keratitler tüm dünyada önemli oküler morbidite sebeplerindendir. Keratit en sık bakterilere sekonder ortaya çıkmakla birlikte özellikle az gelişmiş ve gelişmekte olan ülkelerde mantar keratitleri ön plana çıkmaktadır. Keratitler çok ciddiistenmeyen sonuçlara neden olabileceğinden enfeksiyöz keratitlerin erken tanısı ve agresif tedavisi çok önemlidir. Enfeksiyözkeratitlerde genel olarak tedavi klinik görünüm, mikroskobi ve kültür sonucuna göre planlanır. Tanı ve tedavi seçeneklerindeki yeni gelişmeler enfeksiyöz keratitlerin prognozunu iyileştirmektedir. Bu derlemede bakteryel ve fungal keratitlerin klasiktedavilerinden kısaca bahsedildikten sonra her iki grup enfeksiyon ajanının tedavi yaklaşımlarındaki yeniliklerden söz edilecektir.

Anahtar Kelime:

Konular: Göz Hastalıkları

New Developments in the Treatment of Bacterial and Fungal Keratiti

Öz:

Infectious keratitis is an important cause of ocular morbidity worldwide. Although keratitis most commonly occurs due tobacterial infections, fungal infections may predominate in tropical and rural areas, particularly in underdeveloped and developing countries. Early diagnosis and aggressive treatment of infectious keratitis is of paramount importance as infectiouskeratitis can cause very serious adverse outcomes. Treatment is generally planned according to the clinical appearance, microscopic examination and culture results. New developments in the diagnosis and treatment options have substantially improved the prognosis of infectious keratitis. In this review we will briefly touch on the classical treatment of bacterial andfungal keratitis and then discuss the innovations in the treatment approach.

Anahtar Kelime:

Konular: Göz Hastalıkları

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Yıldırım N. Enfeksiyöz kornea hastalıklarında tedavi ve ilaçlar, in Kornea. Epsilon: İstanbul 2009;309-28.
2. Arffa R.C. Infectious Ulcerative Keratitis: Bacterial, in Grayson's Diseases of the cornea. Mosby: St.Louis, 1991;163-98.
3. Sueke HSJ. Neal TJ. Horsburgh M. Gilbert R. Kaye SB. New Developments in Antibacterial Che mo the - rapy for Bacterial Keratitis in Corneal Diseases. In: LF. Reinhard T, Editor. Springer-Verlag Berlin: Heidel berg 2013;30.
4. Ni N. Srinivasan M. McLeod SD. Acharya NR. Liet - man TM. Rose-Nussbaumer J. Use of adjunctive topical corticosteroids in bacterial keratitis. Curr Opin Ophthalmol 2016;27(4):353-7.
5. Tallab RT. and Stone DU. Corticosteroids as a therapy for bacterial keratitis: an evidence-based review of "who, when and why". Br J Ophthalmol 2016;100(6): 731-5.
6. Srinivasan M, Mascarenhas J. Rajaraman R. et al, Steroids for Corneal Ulcers Trial Group. Cortico ste ro - ids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol 2012;130(2): 143-50.
7. Ray KJ. Srinivasan M. Mascarenhas J. et al. Early addition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmol 2014;132(6):737-41.
8. Mah FS. Sanfilippo CM. Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections. Ophthalmol Ther 2016;5(1):1-20.
9. O'Brien TP. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther 2012;29(6):473-90.
10. Carion TW. McWhirter CR. Grewal DK. Berger EA. Ef fi cacy of VIP as Treatment for Bacteria-Induced Ke ra titis Against Multiple Pseudomonas aeruginosa Strains. Invest Ophthalmol Vis Sci 2015;56)11): 6932-40.
11. Bandara M. Sankaridurg P. Zhu H. Hume E. Willcox M. Effect of Salicylic Acid on the Membrane Proteome and Virulence of Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci 2016;57(3):1213-20.
12. Chatterjee S. and Agrawal D. Multi-drug resistant Pseu domonas aeruginosa keratitis and its effective treatment with topical colistimethate. Indian J Ophthalmol 2016;64(2):153-7.
13. Jain R. Murthy SI. Motukupally SR. Jain M. Use of to - pi cal colistin in multiple drug-resistant Pse u do monas aeruginosa bacterial keratitis. Cornea 2014;33(9): 923-7.
14. Bispo PJ. Haas W. Gilmore MS. Biofilms in infections of the eye. Pathogens 2015;4(1):111-36.
15. Bialasiewicz AA. Breidenbach KA. Klauss V. Al-Saeidi RM. Shenoy R. Bischoff G. Clinical management of infectious contact lens complications: from antibiotics to quorum-sensing inhibitors. Expert Rev Ophthalmol 2010;5(6):789-97.
16. Tabibian D. Mazzotta C. Hafezi F. PACK-CXL: Corneal cross-linking in infectious keratitis. Eye Vis (Lond) 2016;3:11.
17. Chan TC. Agarwal T. Vajpayee RB. Jhanji V. Crosslinking for microbial keratitis. Curr Opin Ophthalmol 2016;27(4):348-52.
18. Chan TC. Lau TW. Lee JW. Wong IY. Jhanji V. Wong RL. Corneal collagen cross-linking for infectious keratitis: an update of clinical studies. Acta Ophthalmol 2015;93(8): 689-96.
19. Tuli S. Gray M. Surgical management of corneal infections. Curr Opin Ophthalmol 2016; 27(4):340-7.
20. Chen WL. Lin CT. Hsieh CY. Tu IH. Chen WY. Hu FR. Comparison of the bacteriostatic effects, corneal cytotoxicity, and the ability to seal corneal incisions among three different tissue adhesives. Cornea 2007;26(10): 1228-34.
21. Robaei D. Carnt N. Watson S. Established and emerging ancillary techniques in management of microbial keratitis: a review. Br J Ophthalmol 2016;100 (9):1163-70.
22. Tseng SC. Espana EM. Kawakita T. et al. How does amniotic membrane work? Ocul Surf 2004;2(3):177- 87.
23. Sandinha T. Zaher SS. Roberts F. Devlin HC. Dhillon B. Ramaesh K. Superior forniceal conjunctival advancement pedicles (SFCAP) in the management of acute and impending corneal perforations. Eye (Lond) 2006;20(1):84-9.
24. Yalniz-Akkaya Z. Burcu A. Doğan E. Onat M. Ornek F. Therapeutic penetrating keratoplasty for infectious and non-infectious corneal ulcers. Int Ophthalmol 2015;35(2):193-200.
25. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004;15(4):321-7.
26. Keay LJ. Gower EW. Iovieno A. et al. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. Opht - hal mology 2011;118(5):920-6.
27. Ledbetter EC. Irby NL. Kim SG. In vivo confocal microscopy of equine fungal keratitis. Vet Ophthalmol 2011;14(1):1-9.
28. Kurbanyan K. Hoesl LM. Schrems WA. Hamrah P. Corneal nerve alterations in acute Acanthamoeba and fungal keratitis: an in vivo confocal microscopy study. Eye (Lond) 2012;26(1):126-32.
29. FlorCruz NV. Peczon IV. Evans JR. Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2012;(2):CD004241.
30. Prajna NV. John RK. Nirmalan PK. Lalitha P. Sriniva - san M. A randomised clinical trial comparing 2% eco - nazole and 5% natamycin for the treatment of fungal keratitis. Br J Ophthalmol 2003;87(10):1235-7.
31. Arora R. Gupta D. Goyal J. Kaur R. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. Clin Exp Ophthalmol 2011;39(5):434-40.
32. Mahdy RA. Nada WM. Wageh MM. Topical amphotericin B and subconjunctival injection of fluconazole (combination therapy) versus topical amphotericin B (monotherapy) in treatment of keratomycosis. J Ocul Pharmacol Ther 2010;26(3):281-5.
33. Ciolino JB. Hudson SP. Mobbs AN. A prototype antifungal contact lens. Invest Ophthalmol Vis Sci 2011; 52(9):6286-91.
34. Haddad RS. El-Mollayess GM. Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis. Middle East Afr J Ophthalmol 2012;19(2):265-8.
35. Maharana PK. Sharma N. Nagpal R. Jhanji V. Das S. Vajpayee RB. Recent advances in diagnosis and management of Mycotic Keratitis. Indian J Ophthal - mol 2016;64(5):346-57.
36. Altun A. Kurna SA. Sengor T. et al. Effectiveness of posaconazole in recalcitrant fungal keratitis resistant to conventional antifungal drugs. Case Rep Ophthal - mol Med 2014;2014:701653.
37. Neoh CF. Jacob J. Leung L. et al. Stability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exercise. Antimicrob Agents Chemother 2012;56(6):3435-7.
38. Hurtado-Sarrió M. Duch-Samper A. Cisneros-Lanuza A. Díaz-Llopis M. Peman-Garcíia J. Vazquez-Polo A. Successful topical application of caspofungin in the treatment of fungal keratitis refractory to voriconazole. Arch Ophthalmol 2010;128(7):941-2.
39. Ozturk F. Yavas GF. Kusbeci T. et al. Efficacy of topical caspofungin in experimental fusarium keratitis. Cornea 2007;26(6):726-8.
40. Matsumoto Y. Dogru M. Goto E. Fujishima H. Tsubota K. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review. Cornea 2005;24(6):748-53.
41. Matsumoto Y. Murat D. Kojima T. Shimazaki J. Tsu - bota K. The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis. Br J Ophthalmol 2011;95 (10):1406-9.
42. El-Mofty HM. Abdelhakim MA. El-Miligi MF. El-Naba - rawi MA. Khalil IA. A new combination formula for treatment of fungal keratitis: an experimental study. J Ophthalmol 2014;2014:173298.
43. Prajna NV. Krishnan T. Mascarenhas J. et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol 2013;131(4):422-9.
44. Prajna NV. et al. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial. JAMA Opht halmol, 2016;134(12):1365-72.
45. Prajna NV. Krishnan T. Rajaraman R. et al. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Cli - ni cal Trial. JAMA Ophthalmol 2016;134(12):1365-72.
46. Vajpayee RB. Shafi SN. Maharana PK. Sharma N. Jhanji V. Evaluation of corneal collagen cross-linking as an additional therapy in mycotic keratitis. Clin Exp Ophthalmol 2015;43(2):103-7.
47. Uddaraju M. Mascarenhas J. Das MR. et al. Corneal Cross-linking as an Adjuvant Therapy in the Mana ge - ment of Recalcitrant Deep Stromal Fungal Keratitis: A Randomized Trial. Am J Ophthalmol 2015;160(1): 131-4.e5.
48. Richoz O. Moore J. Hafezi F. Moore T. Corneal crosslinking as an adjuvant therapy in the management of recalcitrant deep stromal fungal keratitis: a randomized trial. Am J Ophthalmol 2015;160(3):616-7.
49. Bilgihan K. Kalkanci A. Ozdemir HB. et al. Evaluation of Antifungal Efficacy of 0.1% and 0.25% Riboflavin with UVA: A Comparative In Vitro Study. Curr Eye Res 2016;41(8):1050-6.
50. Tabibian D. Richoz O. Riat A. Schrenzel J. Hafezi F. Accelerated photoactivated chromophore for keratitiscorneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. J Refract Surg 2014;30(12):855-7.

APA	yildirim n, Atalay E (2017). Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. , 29 - 40.
Chicago	yildirim nilgün,Atalay Eray Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. (2017): 29 - 40.
MLA	yildirim nilgün,Atalay Eray Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. , 2017, ss.29 - 40.
AMA	yildirim n,Atalay E Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. . 2017; 29 - 40.
Vancouver	yildirim n,Atalay E Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. . 2017; 29 - 40.
IEEE	yildirim n,Atalay E "Bakteryel ve Fungal Keratit Tedavisinde Yenilikler." , ss.29 - 40, 2017.
ISNAD	yildirim, nilgün - Atalay, Eray. "Bakteryel ve Fungal Keratit Tedavisinde Yenilikler". (2017), 29-40.

APA	yildirim n, Atalay E (2017). Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. MN Oftalmoloji, 24(1 Korneada Yenilikl), 29 - 40.
Chicago	yildirim nilgün,Atalay Eray Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. MN Oftalmoloji 24, no.1 Korneada Yenilikl (2017): 29 - 40.
MLA	yildirim nilgün,Atalay Eray Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. MN Oftalmoloji, vol.24, no.1 Korneada Yenilikl, 2017, ss.29 - 40.
AMA	yildirim n,Atalay E Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. MN Oftalmoloji. 2017; 24(1 Korneada Yenilikl): 29 - 40.
Vancouver	yildirim n,Atalay E Bakteryel ve Fungal Keratit Tedavisinde Yenilikler. MN Oftalmoloji. 2017; 24(1 Korneada Yenilikl): 29 - 40.
IEEE	yildirim n,Atalay E "Bakteryel ve Fungal Keratit Tedavisinde Yenilikler." MN Oftalmoloji, 24, ss.29 - 40, 2017.
ISNAD	yildirim, nilgün - Atalay, Eray. "Bakteryel ve Fungal Keratit Tedavisinde Yenilikler". MN Oftalmoloji 24/1 Korneada Yenilikl (2017), 29-40.